This clinical trial is focused on studying the treatment of localized ER-positive breast cancer in older patients. The study is exploring the use of a medication called palbociclib, which is being considered as an alternative to traditional chemotherapy. Palbociclib is a type of drug known as an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, which are proteins that help control cell division. The trial aims to determine if using palbociclib along with at least five years of hormone therapy can be as effective as chemotherapy followed by hormone therapy in preventing the return of cancer.

Participants in the study will receive palbociclib for two years as part of their treatment plan. The study will compare the outcomes of patients receiving this treatment with those receiving standard chemotherapy. The trial will monitor the patients over several years to assess the effectiveness of the treatment in preventing cancer recurrence and to evaluate the overall survival rates. The study will also track any side effects experienced by the participants and how these might affect their quality of life.

The trial is designed for patients who have undergone surgery for their breast cancer and are at high risk of the cancer returning. It is specifically targeting older patients, as they may have different treatment needs compared to younger individuals. The study will help determine if palbociclib can offer a viable alternative to chemotherapy, potentially providing a treatment option with fewer side effects for this group of patients.